Clinical Outcome of Topical Interferon Alpha-2b Cream in Phase II Trial for LSIL/CIN 1 Patients


Objectives: Interferon alpha-2b possesses variable activity against human papillomavirus (HPV) associated cervical intraepithelial neoplasia (CIN). No topical therapy is currently available for treatment of early stage CIN. We evaluated a new patented drug delivery technology in order to achieve topical efficacy. Methods: Two separate studies were conducted in parallel. IFN002 (treatment group) was an open label study. Twenty patients with Pap IIW, III and IIID (CIN1) were treated with intravaginal application of Interferon alpha-2b cream (5 g, 2 MIU/g) three times a week (alternate days) for 6 weeks with 6 weeks of follow up to determine its effect on cytologic and colposcopic assessment. HPV001 (control group) was a 12 week observational study. Both studies had similar inclusion/exclusion criteria and patient population. Results: In IFN002, 8 of 20 patients (40%) in the ITT population showed resolution of abnormal Pap smear during the 12 weeks following start of treatment (responders). In HPV001, 7 of 21 patients (33.3%) were regressors (p = 0.45, one-sided FET). In the PP population, 7 of 12 (58.3%) patients in IFN002 were regressors com-pared to 7 regressors of 19 patients (36.8%) in HPV001 patients (p = 0.21, one-sided FET). Among patients with Pap IIID, 8 of 14 patients in IFN002 showed resolution of abnormal Pap smear, while 4 of 14 patients resolved in HPV001 (one-sided FET, p = 0.13). Conclusions: Interferon alpha-2b cream (5 g, 2 MIU/g) may be an effective treatment for CIN 1 patients, and future investigation is warranted.

Share and Cite:

R. Kurzeja, G. Böhmer and A. Schneider, "Clinical Outcome of Topical Interferon Alpha-2b Cream in Phase II Trial for LSIL/CIN 1 Patients," Journal of Cancer Therapy, Vol. 2 No. 2, 2011, pp. 203-208. doi: 10.4236/jct.2011.22026.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] K. A. Ault, “Epidemiology and Natural History of Human Papillomavirus Infections in the Female Genital Tract,” Infectious Diseases in Obstetrics and Gynecology, Vol. 2006, No.1, January 2006, pp. 1-5.
[2] M. Schiffman and D. Solomon, “Findings to Date from the ASCUS-LSIL Triage Study (ALTS),” Archives of Pathology and Laboratory Medicine, Vol. 127, No. 8, August 2003, pp. 946-949.
[3] The ASCUS-LSIL Triage Study (ALTS) Group, “A Randomized Trial on the Management of Low-Grade Squamous Intraepithelial Lesions Cytology Interpretations,” American Journal of Obstetrics and Gynecology, Vol. 188, No. 6, June 2003, pp. 1393-1400.
[4] M. Kyrgiou, G. Koliopoulos, P. Martin-Hirsch, M. Arbyn, W. Prendiville and E. Paraskeviadis, “Obstetric Outcomes after Conservative Treatment for Intraepithelial or Early Invasive Cervical Lesions: Systematic Review and Metaanalysis,” The Lancet, Vol. 367, No. 9509, February 2006, pp. 489-498. doi:10.1016/S0140-6736(06)68181-6
[5] C. Penna, M. G. Fallani, R. Gordigiani, L. Sonni, G. L. Taddei and M. Marchionni, “Intralesional Beta-Interferon Treatment of Cervical Intraepithelial Neoplasia Associated with Human Papillomavirus Infection,” Tumori, Vol. 80, No. 2, February 1994, pp. 146-150.
[6] M. Katesmark, S. Coulter-Smith, K. Reynolds and F. Lawton, “A Pilot Study of the Efficacy and Tolerability of Intralesional Recombinant Human Beta Interferons in Cervical Intraepithelial Neoplasia,” Annals Academy of Medicine Singapore, Vol. 28, No. 6, November 1999, pp. 775-777.
[7] R. Zarcone, P. Bellini, G. Cardone and A Cardone, “Treatment of Cervix Condylomata with Alpha-IFN Leucocytar,” Clinical and Experimental Obstetrics and Gynecology, Vol. 22, No. 4, March 1995, pp. 326-329.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.